Nabriva Therapeutics share price logo

Nabriva Therapeutics

OTC: NBRVF

Live

as on

Nabriva Therapeutics Stock Performance

as on June 9, 2026 at 2:57 am IST

Nabriva Therapeutics share price movements today

Previous Close
-
Open
-
Volume
200.0
Market Cap
$1.7M

Nabriva Therapeutics Historical Returns

1 Month Return
0 %
3 Month Return
0 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Nabriva Therapeutics Stock Fundamentals & Key Indicators

Check Nabriva Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.7M

EPS (TTM)

-17.98

Dividend Yield

0.00%

PE Ratio (TTM)

0

Industry PE ratio

-5.75

PEG Ratio

-0.00

Return On Equity TTM

-201.91%

Nabriva Therapeutics stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Nabriva Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Nabriva Therapeutics image
Nabriva Therapeutics
NA$1.7MNANA19.87%0.00%

Nabriva Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Total Revenue
2
7
8
8
7
8
8
10
7
2
Gross Profit
2
4
4
3
4
4
4
-5
3
-6
Operating Income
-13
-11
-10
-12
-11
-10
-11
-22
-8
-12
EBITDA
-13
-10
-10
-13
-11
-10
-10
-22
-8
-12
Interest Expense
0
0
0
0
0
0
0
0
0
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-13
-11
-10
-13
-11
-10
-10
-22
-8
-12
Income Tax Expense
0
0
0
0
0
0
0
0
-
-
Net Income
-13
-11
-10
-13
-11
-11
-11
-22
-8
-12
Net Profit Margin
97.09%
53.30%
50.13%
40.90%
56.17%
49.24%
49.73%
-56.61%
41.53%
-252.53%

Nabriva Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Total Revenue
-
6
7
5
27
35
Gross Profit
-
6
7
3
14
7
Operating Income
-73
-114
-79
-66
-48
-55
EBITDA
-72
-114
-78
-66
-47
-54
Interest Expense
0
0
3
1
0
0
Depreciation
0
0
0
0
0
0
Income Before Tax
-73
-114
-82
-69
-48
-55
Income Tax Expense
1
0
0
0
0
1
Net Income
-74
-114
-82
-69
-49
-57
Net Profit Margin
0.00%
100.00%
99.10%
68.45%
51.69%
19.87%

Nabriva Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Net Income
-13
-11
-10
-13
-11
-11
-11
-22
-8
-12
Operating Cash Flow
-21
-18
-13
-6
-15
-13
-6
-1
-5
0
Investing Cash Flow
0
0
0
0
0
0
0
0
0
0
Financing Cash Flow
34
25
4
2
2
0
1
0
-4
0
Change in Cash
13
6
-9
-4
-13
-13
-5
-2
-10
0

Nabriva Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Net Income
-74
-114
-82
-69
-49
-57
Operating Cash Flow
-69
-72
-71
-71
-59
-36
Investing Cash Flow
49
-4
0
0
0
0
Financing Cash Flow
72
92
56
26
66
1
Change in Cash
53
15
-15
-44
6
-35

About Nabriva Therapeutics

Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key product is XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. XENLETA is also currently advancing through Phase I clinical trials for additional indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Moreover, the company is progressing CONTEPO, an epoxide antibiotic designed to address complicated urinary tract infections, which is concurrently in Phase I clinical evaluation for peri-operative prophylaxis. Founded in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and is headquartered in Dublin, Ireland.
OrganisationNabriva Therapeutics
HeadquartersAlexandra House, Dublin, DU, 4, IE
IndustryBiotechnology
CEOH. Michael Hogan

FAQs

What is Nabriva Therapeutics's market capitalisation today?

Nabriva Therapeutics market capitalisation is $0.00T as on .

How to invest in Nabriva Therapeutics Stock (NBRVF) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Nabriva Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Nabriva Therapeutics Stock (NBRVF) from India?

Indian investors can start investing in Nabriva Therapeutics (NBRVF) shares with as little as ₹94.94000244140625 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in Nabriva Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Learn more about fractional shares .